Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study
Journal of the American Heart Association, 2026;:e046302
Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications
Current opinion in HIV and AIDS, 2026
N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement
Cell reports, 2026;45(7):117718
Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway
Clinical science (London, England : 1979);140(8):1695-1708
[Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic study in vitro]
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics;28(7):877-884
Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study
The lancet. Psychiatry;13(8):669-677
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data
British journal of clinical pharmacology, 2026
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study
Journal of translational medicine, 2026
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study
BMC endocrine disorders, 2026
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2026
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use
Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026;:104872
Real-World Kidney and Glycaemic Outcomes Following Semaglutide Initiation in Adults with Type 2 Diabetes and Mild Chronic Kidney Disease
Journal of clinical medicine, 2026;15(14)
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists
Cardiovascular toxicology, 2026;26(7)
Thermosensitive Hydrogels for Sustained Semaglutide Release: Overcoming Weight Loss Plateau in Diet-Induced Obese Rats
Pharmaceutical development and technology, 2026;:1-27
Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison
Diabetes, obesity & metabolism, 2026
Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk
Diabetes & metabolism journal, 2026
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
International journal of obesity (2005), 2026
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
The lancet. Gastroenterology & hepatology, 2026
GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder
The Journal of clinical psychiatry, 2026;87(3)
Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches
Nutrients, 2026;18(14)